<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">53003</article-id><article-id pub-id-type="doi">10.7554/eLife.53003</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group></article-categories><title-group><article-title>STRIPAK directs PP2A activity toward MAP4K4 to promote oncogenic transformation of human cells</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-118818"><name><surname>Kim</surname><given-names>Jong Wook</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-3021-7193</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-118817"><name><surname>Berrios</surname><given-names>Christian</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-118819"><name><surname>Kim</surname><given-names>Miju</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-118820"><name><surname>Schade</surname><given-names>Amy E</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-0342-8251</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-86695"><name><surname>Adelmant</surname><given-names>Guillaume</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-118821"><name><surname>Yeerna</surname><given-names>Huwate</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-118823"><name><surname>Damato</surname><given-names>Emily</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-118827"><name><surname>Iniguez</surname><given-names>Amanda Balboni</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-15033"><name><surname>Florens</surname><given-names>Laurence</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-114478"><name><surname>Washburn</surname><given-names>Michael P</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-7568-2585</contrib-id><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-118828"><name><surname>Stegmaier</surname><given-names>Kim</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-4531"><name><surname>Gray</surname><given-names>Nathanael S</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5354-7403</contrib-id><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-118826"><name><surname>Tamayo</surname><given-names>Pablo</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-110118"><name><surname>Gjoerup</surname><given-names>Ole</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-77304"><name><surname>Marto</surname><given-names>Jarrod A</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf4"/></contrib><contrib contrib-type="author" corresp="yes" id="author-8660"><name><surname>DeCaprio</surname><given-names>James</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf5"/></contrib><contrib contrib-type="author" corresp="yes" id="author-5558"><name><surname>Hahn</surname><given-names>William C</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-2840-9791</contrib-id><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="corresp" rid="cor2">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf6"/></contrib><aff id="aff1"><institution>Broad Institute of Harvard and MIT</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United States</country></aff><aff id="aff2"><institution content-type="dept">Department of Medical Oncology</institution>, <institution>Dana-Farber Cancer Institute</institution>, <addr-line><named-content content-type="city">Boston</named-content></addr-line>, <country>United States</country></aff><aff id="aff3"><institution content-type="dept">The Blais Proteomics Center</institution>, <institution>Dana-Farber Cancer Institute</institution>, <addr-line><named-content content-type="city">Boston</named-content></addr-line>, <country>United States</country></aff><aff id="aff4"><institution content-type="dept">Division of Medical Genetics, School of Medicine</institution>, <institution>University of California, San Diego</institution>, <addr-line><named-content content-type="city">San Diego</named-content></addr-line>, <country>United States</country></aff><aff id="aff5"><institution>Stowers Institute for Medical Research</institution>, <addr-line><named-content content-type="city">Kansas City</named-content></addr-line>, <country>United States</country></aff><aff id="aff6"><institution content-type="dept">Department of Cancer Biology</institution>, <institution>Dana-Farber Cancer Institute</institution>, <addr-line><named-content content-type="city">Boston</named-content></addr-line>, <country>United States</country></aff><aff id="aff7"><institution content-type="dept">Department of Medical Oncology</institution>, <institution>Dana-Farber Cancer Institue</institution>, <addr-line><named-content content-type="city">Boston</named-content></addr-line>, <country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-1072"><name><surname>Davis</surname><given-names>Roger J</given-names></name><role>Reviewing editor</role><aff><institution>University of Massachusetts Medical School</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>james_decaprio@dfci.harvard.edu</email> (JD);</corresp><corresp id="cor2"><label>*</label>For correspondence: <email>william_hahn@dfci.harvard.edu</email> (WH);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>08</day><month>01</month><year>2020</year></pub-date><volume>9</volume><elocation-id>e53003</elocation-id><history><date date-type="received"><day>23</day><month>10</month><year>2019</year></date><date date-type="accepted"><day>07</day><month>01</month><year>2020</year></date></history><permissions><copyright-statement>Â© 2020, Kim et al</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Kim et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-53003-v1.pdf"/><abstract><p>Alterations involving serine-threonine phosphatase PP2A subunits occur in a range of human cancers and partial loss of PP2A function contributes to cell transformation. Displacement of regulatory B subunits by the SV40 Small T antigen (ST) or mutation/deletion of PP2A subunits alters the abundance and types of PP2A complexes in cells, leading to transformation. Here we show that ST not only displaces common PP2A B subunits but also promotes A-C subunit interactions with alternative B subunits (B', striatins) that are components of the Striatin-interacting phosphatase and kinase (STRIPAK) complex. We found that STRN4, a member of STRIPAK, is associated with ST and is required for ST-PP2A-induced cell transformation. ST recruitment of STRIPAK facilitates PP2A-mediated dephosphorylation of MAP4K4 and induces cell transformation through the activation of the Hippo pathway effector YAP1. These observations identify an unanticipated role of MAP4K4 in transformation and show that the STRIPAK complex regulates PP2A specificity and activity.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>P01 CA203655</award-id><principal-award-recipient><name><surname>DeCaprio</surname><given-names>James</given-names></name><name><surname>Hahn</surname><given-names>William C</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>U01 CA217885</award-id><principal-award-recipient><name><surname>Kim</surname><given-names>Jong Wook</given-names></name><name><surname>Yeerna</surname><given-names>Huwate</given-names></name><name><surname>Tamayo</surname><given-names>Pablo</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>Kim Stegmaier, has previously consulted for Novartis and Rigel Pharmaceuticals and receives grant funding from Novartis on unrelated topics.</p></fn><fn fn-type="conflict" id="conf3"><p>Nathanael S Gray, is a founder, science advisory board member (SAB) and equity holder in Gatekeeper, Syros, Petra, C4, B2S and Soltego. Also receives or has received research funding from Novartis, Takeda, Astellas, Taiho, Janssen, Kinogen, Voronoi, Her2llc, Deerfield and Sanofi.</p></fn><fn fn-type="conflict" id="conf4"><p>Jarrod A Marto, serves on the scientific advisory board of 908 Devices.</p></fn><fn fn-type="conflict" id="conf5"><p>James DeCaprio, has served as a consultant to Merck &amp; Co, Inc and has received research funding from Constellation Pharmaceuticals, Inc.</p></fn><fn fn-type="conflict" id="conf6"><p>William C Hahn, Reviewing editor, <italic>eLife</italic>, is a consultant for Thermo Fisher, AjuIB, MPM Capital, iTeos, Tyra Biosciences, Frontier Medicines and Parexel. WCH is a founder and serves on the scientific advisory board for KSQ Therapeutics.</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All of the animals were handled according to approved institutional animal care and use committee (IACUC) protocols of the Dana-Farber Cancer Institute under assurance number A3023-01. The protocol was approved by the Committee on the Ethics of Animal Experiments of the Dana-Farber Cancer Institute (Permit Number:04-101).</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>The RNAseq data for MAP4K4 suppression experiments have been deposited in the Gene Expression Omnibus (GEO) under accession code GSE118272. Raw mass spectrometry data files for SILAC and iTRAQ are available for free download at ftp://massive.ucsd.edu/MSV000084422/. MudPIT mass spectrometry data files are available for download at Massive: ftp://massive.ucsd.edu/MSV000084662/ and ProteomeXchange:http://proteomecentral.proteomexchange.org/cgi/GetDataset?ID=PXD016628.</p><p>The following datasets were generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><collab>Kim JW</collab><collab>Kim M</collab><collab>DeCaprio J</collab><collab>Hahn W</collab></person-group><year iso-8601-date="2019">2019</year><source>STRIPAK directs PP2A activity to promote oncogenic transformation</source><ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE118272">https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE118272</ext-link><comment>NCBI Gene Expression Omnibus, GSE118272</comment></element-citation><element-citation id="dataset2" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><collab>Berrios C</collab><collab>Florens L</collab><collab>Washburn MP</collab><collab>DeCaprio J</collab></person-group><year iso-8601-date="2019">2019</year><source>MudPIT analysis of STRN4 interacting proteins from HEK TER cells expressing either SV40 ST or GFP</source><ext-link ext-link-type="uri" xlink:href="http://proteomecentral.proteomexchange.org/cgi/GetDataset?ID=PXD016628">http://proteomecentral.proteomexchange.org/cgi/GetDataset?ID=PXD016628</ext-link><comment>ProteomeXchange, PXD016628</comment></element-citation></p></sec><supplementary-material><ext-link xlink:href="elife-53003-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>